SI-BONE Gestione
Criteri Gestione verificati 2/4
SI-BONE Il CEO è Laura Francis, nominato in Apr2021, e ha un mandato di 5.17 anni. la retribuzione annua totale è $ 7.45M, composta da 9.2% di stipendio e 90.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.12% delle azioni della società, per un valore di $ 7.52M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.2 anni e 16 anni.
Informazioni chiave
Laura Francis
Amministratore delegato
US$7.5m
Compenso totale
| Percentuale dello stipendio del CEO | 9.19% |
| Mandato del CEO | 5.2yrs |
| Proprietà del CEO | 1.1% |
| Durata media del management | 5.2yrs |
| Durata media del Consiglio di amministrazione | 16yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • Jun 06
SIBN: Raised 2026 Revenue Guidance Will Support Further Upside Potential
Analysts kept their $18.00 price target for SI-BONE steady, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and forward P/E, without a clear shift in overall conviction. What's in the News SI-BONE issued raised earnings guidance for 2026, with worldwide revenue now expected in a range of $230 million to $233 million, compared with prior guidance of $228.5 million to $232.5 million.Aggiornamento della narrazione • May 22
SIBN: 2026 Guidance And Trauma Partnership Will Drive Further Upside
Analysts have trimmed their price target on SI-BONE from $22.00 to $18.00 as updated assumptions now reflect slightly lower revenue growth, a modestly reduced profit margin outlook, and a lower future P/E multiple, partly offset by a small adjustment to the discount rate. What's in the News SI-BONE issued earnings guidance for 2026, with worldwide revenue expected in a range of $228.5 million to $232.5 million, implying year-over-year growth of about 14% to 16% (Key Developments).Articolo di analisi • May 14
Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its latest first-quarter results and things are looking bullish. Results...Aggiornamento della narrazione • Apr 12
SIBN: 2026 Guidance And Trauma Partnership Will Support Further Upside
Analysts have kept SI-BONE's price target steady at $22.00, citing only modest tweaks to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions, rather than any major change in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac joint fusion, expanding access to these products through Smith+Nephew's trauma portfolio and SI-BONE's existing sales channel (Key Developments).Aggiornamento della narrazione • Mar 29
SIBN: 2026 Outlook And Pelvic Fixation Partnership Will Support Upside
Analysts now hold their price target for SI-BONE steady at $22.00. This reflects only small tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially shift their overall valuation view.Aggiornamento della narrazione • Mar 11
SIBN: 2026 Revenue Outlook And Pelvic Fixation Deal Will Support Upside
Analysts have held their SI-BONE price target steady at $22.00, with only modest tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E, reflecting fine tuning rather than a shift in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac (SI) joint fusion, broadening access to these products through Smith+Nephew's trauma channel alongside SI-BONE's existing salesforce (Key Developments).Aggiornamento della narrazione • Feb 25
SIBN: 2026 Revenue Outlook And New Distribution Deal Will Support Upside
Analysts have trimmed their price target for SI-BONE from $23.00 to $22.00, reflecting updated assumptions that include slightly lower revenue growth expectations, a modestly higher profit margin outlook, and a revised forward P/E multiple. What's in the News SI-BONE issued earnings guidance for 2026, projecting worldwide revenue in a range of $228.5 million to $232.5 million, with implied year over year growth guidance of about 14% to 16% (company guidance).Aggiornamento della narrazione • Jan 19
SIBN: Higher 2025 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their fair value estimate for SI-BONE at $23.00. They made small adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support this reaffirmed target.Aggiornamento della narrazione • Jan 04
SIBN: Raised 2025 Revenue Guidance Will Drive Stronger Profitability And Share Price Upside
Analysts have modestly lowered their price target on SI-BONE to 23.00 dollars per share, reflecting a slightly higher discount rate and a marginally lower expected future price to earnings multiple, even as they factor in stronger long term revenue growth prospects. What's in the News SI-BONE raised its 2025 revenue guidance to a range of 198 million to 200 million dollars, up from 195 million to 198 million dollars previously.Aggiornamento della narrazione • Dec 19
SIBN: Raised Revenue Guidance Will Support Stronger Profitability And Share Price Upside
Analysts have raised their price target on SI-BONE from 20 dollars to 23 dollars, citing slightly stronger expectations for revenue growth, profitability, and long term valuation multiples. What's in the News Company raised 2025 revenue guidance to a range of 198 million dollars to 200 million dollars, up from a prior range of 195 million dollars to 198 million dollars, signaling increased confidence in demand trends (company guidance filing) The updated outlook implies faster top line growth than previously anticipated and supports analysts' upward revisions to price targets and long term valuation assumptions (company guidance filing) The narrowing of the revenue guidance range suggests greater visibility into procedure volumes and commercial execution for the remainder of the year (company guidance filing) Valuation Changes The fair value estimate has risen slightly from 20 dollars to 23 dollars per share, reflecting modestly stronger growth and profitability assumptions.Articolo di analisi • Nov 13
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its third-quarter report and things are looking bullish. Revenues and...Articolo di analisi • Nov 12
Getting In Cheap On SI-BONE, Inc. (NASDAQ:SIBN) Might Be Difficult
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.1x may not look like an appealing investment...Articolo di analisi • Jun 26
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • May 09
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) investors will be delighted, with the company turning in some strong numbers with its...Articolo di analisi • May 08
Revenues Tell The Story For SI-BONE, Inc. (NASDAQ:SIBN) As Its Stock Soars 30%
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders would be excited to see that the share price has had a great month, posting...Articolo di analisi • Mar 27
SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Nuova narrazione • Mar 26
TORQ And TNT Will Expand Market Reach In 2025
Strong product launches and a robust innovation pipeline suggest promising future revenue growth and strengthened market positioning.Articolo di analisi • Jan 19
SI-BONE, Inc. (NASDAQ:SIBN) Looks Just Right With A 26% Price Jump
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders have had their patience rewarded with a 26% share price jump in the last...Articolo di analisi • Nov 04
Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues
There wouldn't be many who think SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 3.7x is worth a...Articolo di analisi • Sep 25
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Articolo di analisi • Apr 01
SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.8x might make it look like a sell right now...Articolo di analisi • Feb 29
Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report
It's been a sad week for SI-BONE, Inc. ( NASDAQ:SIBN ), who've watched their investment drop 14% to US$17.35 in the...Articolo di analisi • Feb 28
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Nov 12
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Aug 09
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Apr 20
Is SI-BONE (NASDAQ:SIBN) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Jan 01
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$17m |
| Dec 31 2025 | US$7m | US$685k | -US$19m |
| Sep 30 2025 | n/a | n/a | -US$22m |
| Jun 30 2025 | n/a | n/a | -US$24m |
| Mar 31 2025 | n/a | n/a | -US$27m |
| Dec 31 2024 | US$7m | US$652k | -US$31m |
| Sep 30 2024 | n/a | n/a | -US$37m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$43m |
| Dec 31 2023 | US$4m | US$622k | -US$43m |
| Sep 30 2023 | n/a | n/a | -US$44m |
| Jun 30 2023 | n/a | n/a | -US$48m |
| Mar 31 2023 | n/a | n/a | -US$55m |
| Dec 31 2022 | US$5m | US$604k | -US$61m |
| Sep 30 2022 | n/a | n/a | -US$65m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$62m |
| Dec 31 2021 | US$3m | US$527k | -US$57m |
| Sep 30 2021 | n/a | n/a | -US$51m |
| Jun 30 2021 | n/a | n/a | -US$45m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$2m | US$386k | -US$44m |
| Sep 30 2020 | n/a | n/a | -US$44m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$2m | US$375k | -US$38m |
Compensazione vs Mercato: La retribuzione totale di Laura ($USD 7.45M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.70M ).
Compensazione vs guadagni: La retribuzione di Laura è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Laura Francis (59 yo)
5.2yrs
Mandato
US$7,453,235
Compensazione
Ms. Laura A. Francis, MBA, has been an Independent Director of Bruker Corporation since February 18, 2025. She serves as Director at Galvanize Therapeutics, Inc. from November 2025. She serves as Chief Exe...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 18.2yrs | US$255.35k | 0.20% $ 1.4m | |
| CEO & Director | 5.2yrs | US$7.45m | 1.12% $ 7.5m | |
| COO & CFO | 5.2yrs | US$2.79m | 0.17% $ 1.1m | |
| Chief Business & Legal Affairs Officer | 9.8yrs | US$2.36m | 0.31% $ 2.1m | |
| Advisor | 9.9yrs | US$2.45m | 0.36% $ 2.4m | |
| Senior VP of Engineering & CTO | no data | Nessun dato | Nessun dato | |
| Vice President of Financial Planning & Analysis and Investor Relations | no data | Nessun dato | Nessun dato | |
| Vice President of Product & Marketing | less than a year | Nessun dato | Nessun dato | |
| Senior Vice President of Clinical | 5yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer & VP of Medical Affairs | no data | Nessun dato | Nessun dato | |
| Chief Commercial Officer | 5.2yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Market Access & Reimbursement | less than a year | Nessun dato | Nessun dato |
5.2yrs
Durata media
59yo
Età media
Gestione esperta: Il team dirigenziale di SIBN è esperto e expertise (durata media dell'incarico 5.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 18.2yrs | US$255.35k | 0.20% $ 1.4m | |
| CEO & Director | 5.2yrs | US$7.45m | 1.12% $ 7.5m | |
| Lead Independent Director | 18.2yrs | US$240.35k | 0.13% $ 862.5k | |
| Independent Director | 6.5yrs | US$235.35k | 0.054% $ 365.0k | |
| Independent Director | 13.4yrs | US$215.35k | 0.28% $ 1.9m | |
| Member of Medical Advisory Board | 16.4yrs | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | 16.4yrs | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | 16.4yrs | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | 15.5yrs | Nessun dato | Nessun dato | |
| Independent Director | 5.3yrs | US$220.35k | 0.054% $ 363.5k | |
| Member of Surgeon Advisory Board | no data | Nessun dato | Nessun dato |
16.0yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di SIBN è composto da personale esperto e esperto (durata media dell'incarico 16 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/08 20:02 |
| Prezzo dell'azione a fine giornata | 2026/06/08 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
SI-BONE, Inc. è coperta da 15 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Travis Steed | BofA Global Research |
| Caitlin Cronin | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |